Aligos Therapeutics, Inc. (ALGS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO, CA 94080

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

Data as of 2021-09-19 13:31:22 -0400
Market Cap691.115 Million Shares Outstanding42.609 Million Avg 30-day Volume286.507 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE3.36 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.0 52-week High/Low37.51 / 12.82 Next Earnings Date2021-11-04 Price to Cash FLow (P/CF) -26.0794
Data provided by IEX Cloud
View SEC Filings from ALGS instead.

View recent insider trading info

Funds Holding ALGS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALGS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

NIELSEN JACK

  • Director
15,000 2021-06-17 2

WOIWODE THOMAS

  • Director
15,000 2021-06-17 5

NUECHTERLEIN CAROLE

  • Director
15,000 2021-06-17 3

HIRTH PETER

  • Director
15,000 2021-06-17 2

SCOPA JAMES PAUL

  • Director
0 2021-04-26 2

BLATT LAWRENCE CHIEF EXECUTIVE OFFICER

  • Officer
0 2020-12-01 3

CALHOUN LESLEY ANN

  • SEE REMARKS
0 2020-12-01 2

QUAN LUCINDA Y. SEE REMARKS

  • Officer
0 2020-12-01 3

BEIGELMAN LEONID PRESIDENT

  • Officer
  • Director
0 2020-12-01 3

SYMONS JULIAN A. SEE REMARKS

  • Officer
0 2020-12-01 3

NOVO HOLDINGS A/S

  • 10% Owner
No longer subject to file 2020-10-20 2

VIVO CAPITAL VIII, LLC

VIVO CAPITAL FUND VIII, L.P.

VIVO CAPITAL SURPLUS FUND VIII, L.P.

  • 10% Owner
3,547,030 2020-10-20 2

VERSANT VENTURE CAPITAL VI, L.P.

VERSANT VANTAGE I, L.P.

  • 10% Owner
No longer subject to file 2020-10-20 2

WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P.

  • 10% Owner
No longer subject to file 2020-10-20 2

GLAUB KATHLEEN SEREDA

  • Director
59,550 2020-10-15 1

MOLDT PETER

  • Director
0 2020-10-15 1

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
No current insider transactions

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 22:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 21:45:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 21:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 20:45:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 20:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 19:45:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 19:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 18:45:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 18:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 17:45:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 17:15:03 UTC -0.4996 0.5696 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 16:45:03 UTC -0.4001 0.4701 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 16:15:03 UTC -0.4001 0.4701 65000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 15:45:03 UTC -0.4001 0.4701 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 15:15:04 UTC -0.4001 0.4701 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 14:45:02 UTC -0.3544 0.4244 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 14:15:02 UTC -0.3544 0.4244 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 13:45:02 UTC -0.3544 0.4244 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 13:15:03 UTC -0.3544 0.4244 60000
ALIGOS THERAPEUTICS INC ALGS 2021-09-24 12:45:03 UTC -0.3544 0.4244 60000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin

Elevate your investments